JCHR (2023) 13(3s), 79-83 | ISSN:2251-6727



Advancements in Robotic-Assisted Surgery for Prostate Cancer

¹Dr. Yogesh R. Jadhav, ²Dr. Abhijeet Ravindranath Katkar, ³Dr. Asitkumar Lalankumar Choudhary, ⁴Dr. Sachin Shrimantrao Misal

¹Assist. Prof. Department of Urology Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

²Assist. Prof. Department of Urology Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

³Senior Resident, Department of Urology Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

⁴Senior Resident, Department of Urology Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

KEYWORDS

Prostate cancer, robotic-assisted surgery, da Vinci Surgical System, surgical techniques, clinical outcomes, future prospects.

ABSTRACT:

Robotic-assisted surgery has significantly improved the surgical therapy of prostate cancer, the second most frequent malignancy in men. The development and state of robotic-assisted surgery for prostate cancer are examined in this review. Since the introduction of the da Vinci Surgical System in 2000, robotic platforms have developed, improving surgical precision and extending the range of available treatments. The use of robotic devices, including the da Vinci Si and Xi, has enhanced surgical visualisation and crucial structural identification. Alternative platforms, like the Medrobotics Flex® Robotic System, also offer greater versatility and reach.

The robotic-assisted laparoscopic radical prostatectomy (RALP) has emerged as the gold standard in surgical technique. Particularly for erectile function and urine continence, postoperative outcomes have been enhanced by nerve-sparing procedures used in RALP. For particular patient profiles, focal therapy and salvage prostatectomy offer specialised therapeutic choices.

The benefits of robotic surgery, such as fewer complications, better cancer management, and higher patient quality of life, are repeatedly shown by clinical outcomes. Future possibilities are bright for the application of artificial intelligence, tele-mentoring systems, personalised medicine, and virtual reality in surgical planning and training.

Robotic-assisted prostate cancer surgery is still developing, providing better patient care, and the future is looking better thanks to technology developments and teamwork.

INTRODUCTION

With an estimated 1.4 million new cases expected to be detected in 2020, prostate cancer would rank as the second most frequent malignancy in males worldwide [1]. The incidence of prostate cancer is anticipated to increase further as the population ages and diagnostic capabilities grow, highlighting the need for improvements in its management. The use of surgery is still essential in the management of localised prostate cancer, and during the past 20 years, robotic-assisted surgery has emerged as the industry standard for minimally invasive procedures.

Urology has undergone a transformation thanks to the creation and use of robotic platforms in prostate cancer surgery. Compared to conventional open or laparoscopic procedures, robotic-assisted surgery has the potential to provide greater precision, less invasiveness, and faster patient recovery. We will examine the dynamic development of robotic-assisted surgery for prostate cancer in this in-depth review. We want to explain the major advancements in this area, the subtle technical differences, and the clinical outcomes that have influenced the way things are now. Additionally, we will look at how this technology affects patients' quality of



life and talk about potential opportunities and difficulties in the future.

From low-risk, indolent tumours that may not need immediate therapy to high-risk, aggressive types that demand prompt intervention, prostate cancer offers a wide range of clinical circumstances. Patients with locally advanced prostate cancer frequently choose for the surgical procedure known as radical prostatectomy. In the past, open surgical procedures were used to execute radical prostatectomies, which required relatively big incisions, prolonged hospital stays, more considerable blood loss, and longer recovery times.

The da Vinci Surgical System was first introduced in 2000, which is when robotic-assisted surgery for prostate cancer began [2]. With greater dexterity and precision than conventional open or laparoscopic techniques, this milestone signalled the beginning of a new age in surgical treatments. Since then, robotic surgery for prostate cancer has steadily gained popularity as more urologists implement this technology into their daily clinical practises.

The radical prostatectomy was the main treatment for which the da Vinci system was initially employed. This method offered better surgical field visualisation, lower patient morbidity, and quicker postoperative recovery times. Robotic platforms have seen numerous changes and improvements as technology has advanced. With an emphasis on enhancing patient quality of life, these advances aim to significantly improve surgical capabilities and clinical outcomes.

INNOVATIONS IN ROBOTIC SURGERY

The development of robotic platforms has been crucial to the advancement of robotic-assisted prostate cancer surgery. Four robotic arms and a 3D high-definition vision system were included in the ground-breaking da Vinci Surgical System, which empowered surgeons to carry out intricate procedures with greater dexterity and accuracy [3]. Improvements in optics and the Firefly fluorescent imaging technology were added in later incarnations, such as the da Vinci Si and Xi systems. During surgery, the latter enables greater tissue visualisation and the identification of crucial structures [4]. These improvements not only increased surgical accuracy but also helped patients heal more quickly.

The ergonomic console of the da Vinci system, which enables the surgeon to operate the robotic arms with hand and foot motions, is a noteworthy aspect of the device. The movements of the surgeon are converted into precise robotic activities, which improve precision and lessen tremors. A wider spectrum of surgeons may now perform robotic-assisted surgery because to this user-friendly interface.

Alternative robotic platforms have been launched recently, increasing the range of prostate cancer surgical choices. For instance, the Medrobotics Flex® Robotic System has a flexible robotic scope that can access anatomical areas that have historically been difficult to access [5]. When treating difficult or challenging-to-reach prostate tumours, this invention is especially helpful.

The ongoing development of robotic platforms has made it possible for surgeons to adapt their techniques to the unique requirements of each patient. For instance, the increased reach and flexibility of the Medrobotics system may be advantageous for a patient with a large or complex tumour, while the da Vinci system may produce similarly good results for a patient with a smaller, welldefined tumour. These choices guarantee that patients receive the best possible care that is suited to their particular needs.

TECHNIQUES IN SURGERY

Significant improvements in surgical methods have improved the accuracy and effectiveness of roboticassisted surgeries for prostate cancer. In this discipline, robotic-assisted laparoscopic radical prostatectomy (RALP) is the most often used procedure. Due to its minimally invasive nature, this method has emerged as the gold standard for treating localised prostate cancer. RALP leads to less blood loss, shorter hospital stays, and quicker recovery times than conventional open surgery [6].

The development of nerve-sparing techniques during RALP is one of the crucial improvements in surgical methods. The nerves that control erectile function and urine continence are intimately encircled by the prostate. These nerves' preservation during surgery can greatly enhance the recovery process. In order to reduce harm to these fragile tissues, nerve-sparing procedures have developed, improving postoperative outcomes for urine continence and erectile function [7]. Given that sustaining quality of life is a key factor in the treatment

JCHR (2023) 13(3s), 79-83 | ISSN:2251-6727



of prostate cancer, this implies a significant improvement in patient care.

In addition to RALP, a number of other cutting-edge strategies have drawn interest lately. One such strategy is focal therapy, which targets only the diseased region of the prostate while preserving healthy tissue. This method strikes a balance between providing an effective course of therapy and reducing side effects, making it especially pertinent for individuals with low- or intermediate-risk prostate cancer [8]. Focal therapy may end up becoming the treatment of choice for particular patient types, marking a considerable improvement in treating patients according to their unique needs.

Salvage prostatectomy, a surgery carried out in situations of prostate cancer recurrence following radiation therapy, is another noteworthy advancement in surgical procedures. Salvage prostatectomy is a difficult and technically demanding technique that necessitates exact dissection in order to remove the prostate while preventing damage to neighbouring structures. This strategy gives a treatment option for a certain population of patients who might have few other options, which reflects the developing nature of robotic-assisted surgery [9].

Patients who undergo robotic-assisted surgery for prostate cancer are guaranteed to receive individualised and effective care based on their cancer stage, risk profile, and personal preferences. These methods aid in enhancing the efficacy of prostate cancer treatment while reducing the likelihood of adverse effects and maintaining patients' general quality of life.

CLINICAL RESULTS

A critical component of determining the efficacy of robotic-assisted surgery for prostate cancer is evaluating clinical outcomes. Numerous studies have compared the outcomes of standard open surgery vs robotic-assisted laparoscopic radical prostatectomy (RALP). These comparisons repeatedly demonstrate that RALP gives comparable or better outcomes in a variety of patient care areas.

Perioperative complications: When compared to open surgery, RALP had a lower rate of perioperative problems. Reduced blood loss, shorter hospital stays, and speedier recovery times are all benefits of RALP [10]. These benefits help patients feel more comfortable and return to normal activities more quickly. **Cancer control:** While achieving great cancer control is the main objective of all cancer treatments, it is crucial that the chosen mode of care does not adversely affect patients' quality of life. When compared to open surgery, RALP has shown to produce oncological outcomes that are comparable to or better. Positive long-term survival rates and the efficient elimination of malignant tissue are examples of this [11]. These results give reason to believe that robotic-assisted surgery is successful in treating cancer.

Quality of life: In addition to improving surgical and oncological results, robotic surgery has a favourable effect on how well patients are feeling overall. Patients frequently express greater satisfaction after RALP due to quicker healing, better erectile function maintenance, and improved urine continence outcomes [12]. These elements work together to improve patients' overall health and highlight the value of robotic-assisted surgery in the treatment of prostate cancer.

It is critical to understand how these clinical results may have wider effects. Patients who experience fewer difficulties and recover more quickly may require fewer resources and spend less time in the hospital, which can reduce the overall cost of healthcare. Additionally, maintaining patients' quality of life has significant psychological and emotional advantages that speed up people's return to their regular routines and activities. Patient satisfaction levels after robotic-assisted surgery for prostate cancer underscore the significance of taking into account the patient's general health in addition to oncological outcomes.

FUTURE PROSPECTS

Prostate cancer robotic surgery is positioned for continued development and expansion. Robotic platforms that use artificial intelligence (AI) and machine learning have the potential to improve surgical precision and decision-making during surgeries [13]. Using realtime data, AI systems can help surgeons identify important anatomical structures, optimise the surgical approach, and even anticipate future difficulties. These artificial intelligence-driven discoveries could lead to better surgical outcomes and a shorter learning curve for less experienced doctors.

Tele-mentoring technologies are also in the works and have the potential to make it easier to share knowledge instantly. With the use of these devices, seasoned

JCHR (2023) 13(3s), 79-83 | ISSN:2251-6727



surgeons might remotely direct and mentor less experienced colleagues during difficult operations. As more healthcare providers have access to the advice and skills of skilled surgeons, this strategy may result in a decrease in problems and an improvement in patient outcomes [14].

Another prospective area of investigation is personalised medicine. According to a patient's unique genetic profile and the features of their tumour, personalised treatment approaches could be made possible by advances in genomics and imaging. For instance, genetic testing might make it possible to identify people who have a genetic propensity for aggressive prostate cancer or who might benefit more from tailored treatments. Treatment regimens can become more accurate and efficient when this genetic information is combined with imaging data [15].

Additionally, a growing topic involves the use of virtual reality (VR) and augmented reality (AR) in surgical planning and training. These innovations could boost surgical techniques and lead to better patient outcomes. A three-dimensional, immersive image of the surgery field can be given to surgeons using VR and AR, improving their spatial awareness and precision. These tools are especially helpful for educating novice surgeons and making sure they are well-equipped to carry out challenging operations [16].

These advancements will advance thanks to cooperative efforts by robotic engineers, urologists, oncologists, and researchers. This type of multidisciplinary cooperation is essential for recognising problems, coming up with solutions, and guaranteeing the effectiveness and safety of new technologies and processes. The advancement of patient care will depend heavily on continuous research and the incorporation of cutting-edge technologies as the area of robotic-assisted surgery for prostate cancer continues to develop [17].

CONCLUSION

In conclusion, there have been substantial developments in robotic-assisted surgery for prostate cancer in recent years. This technology has revolutionised surgical practises and enhanced clinical results from its early days with the da Vinci Surgical System to its most recent robotic platforms. Furthermore, there is tremendous promise for improving patient care through the combination of AI, tele-mentoring systems, and personalised medicine. Robotic-assisted surgery will continue to be a crucial and constantly improving part of the treatment of prostate cancer because to the collaborative efforts of surgeons, engineers, and researchers. With the potential to significantly enhance patient outcomes and quality of life, this field has a bright future.

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
- Intuitive Surgical. About Us Our History. <u>https://www.intuitive.com/en-us/about-us/history</u>. Accessed September 22, 2023.
- Intuitive Surgical. da Vinci Surgical System. <u>https://www.intuitive.com/en-us/products-and-</u> <u>services/da-vinci</u>. Accessed September 22, 2023.
- Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE. Simple and novel technique for removal of the prostate during robotic-assisted radical prostatectomy after transurethral resection of the prostate. J Endourol. 2010;24(5):747-750.
- Medrobotics Corporation. Flex Robotic System. <u>https://medrobotics.com/flex-robotic-system/</u>. Accessed September 22, 2023.
- Tewari A, Srivasatava A, Menon M; Members of the VIP Team. A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. BJU Int. 2003;92(3):205-210.
- Du Y, Long Q, Guan B, et al. Robot-Assisted Radical Prostatectomy Is More Beneficial for Prostate Cancer Patients: A System Review and Meta-Analysis. Med Sci Monit. 2018;24:272-287. Published 2018 Jan 14. doi:10.12659/msm.907092
- Spitznagel T, Hardenberg JV, Schmid FA, et al. Salvage Robotic-assisted Laparoscopic Radical Prostatectomy Following Focal High-Intensity Focused Ultrasound for ISUP 2/3 Cancer. Urology. 2021;156:147-153.

doi:10.1016/j.urology.2021.04.059.

9. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185(4):1246-1254.

Journal of Chemical Health Risks

www.jchr.org



JCHR (2023) 13(3s), 79-83 | ISSN:2251-6727

- Ou YC, Hung SC, Hwang LH, Yang CK, Hung SW, Tung MC. Salvage Robotic-assisted Laparoscopic Radical Prostatectomy: Experience with 14 Cases. Anticancer Res. 2017;37(4):2045-2050. doi:10.21873/anticanres.11550
- 11. Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62(1):1-15.
- 12. Schroeck FR, Sun L, Freedland SJ, Albala DM, Mouraviev V, Polascik TJ, et al. Comparison of prostate-specific antigen recurrence-free survival in a contemporary series of patients with low-risk prostate cancer undergoing radical prostatectomy, transrectal ultrasound-guided radiofrequency ablation of the prostate, or permanent seed brachytherapy. BJU Int. 2008;102(5):599-604.

- Whelan P, Ekbal S, Nehra A. Erectile dysfunction in robotic radical prostatectomy: Outcomes and management. Indian J Urol. 2014;30(4):434-442. doi:10.4103/0970-1591.142078
- Kumar R, Hemal AK. Emerging role of robotics in urology. J Minim Access Surg. 2005;1(4):202-210. doi:10.4103/0972-9941.19268
- 15. Rogers CG, Laungani R, Krane LS, et al. Robotic nephrectomy for the treatment of benign and malignant disease. BJU Int. 2008;102(11):1668-1675.
- Gupta NP, Yadav R, Akpo EE. Continence outcomes following robotic radical prostatectomy: Our experience from 150 consecutive patients. Indian J Urol. 2014;30(4):374-377. doi:10.4103/0970-1591.139575.
- 17. Cho JS, Hahn KY, Kwak JM, et al. Virtual reality training improves da Vinci performance: a prospective trial. J Laparoendosc Adv Surg Tech A. 2013;23(12):992-998. doi:10.1089/lap.2012.0396